Hematologic Cancer Articles & Analysis
25 news found
Groups listed by CDC as being at elevated risk of developing invasive mold infections include those who: · Have had a transplant, especially hematopoietic stem cell transplants · Have cancer, especially hematologic cancers like leukemia and lymphoma · Are undergoing cancer treatment ...
Groups listed by the CDC as being at elevated risk of developing invasive mold infections include those who: · Have had a transplant, especially hematopoietic stem cell transplants · Have cancer, especially hematologic cancers like leukemia and lymphoma · Are undergoing cancer ...
” “Each year 300,000 Americans are diagnosed with breast cancer and metastatic breast cancer causes the vast majority of deaths from the disease: more than 43,000 annually. ...
A low percentage of patients received an antiemetic; 8.0% on elacestrant, 3.7% on fulvestrant, and 10.3% on AI, respectively. No hematological safety signal was observed and none of the patients in either of the two treatment arms had sinus bradycardia. Virginia Kaklamani, MD, DSc, breast medical oncologist and professor of medicine, UT Health San Antonio, MD Anderson ...
Goldberg has served most recently as Vice President, Early Clinical Development, at Janssen supervising the clinical programs for multiple myeloma, cellular therapy, prostate cancer, as well as clinical pharmacology. Additionally, she served as the Co-Chair of Janssen Oncology Protocol Review Committee, since January 2021. ...
ByBayer AG
The USA boasts better cancer survival rates than most other developed countries. This was made possible due to a number of factors. In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more ...
Ansell, MD, PhD, Professor of Medicine, Division of Hematology at the Mayo Clinic, with extensive expertise in B-cell malignancies, including both Hodgkin and non-Hodgkin lymphomas Todd A. ...
Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. ...
Other advancing programs include an oral brain penetrant inhibitor of PRMT5, JBI 778, and an oral brain penetrant PDL1 inhibitor, JBI 2174, for neurological cancers among others.” About JBI-802 JBI-802 is novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6. ...
LILRB4 is also expressed on certain hematologic cancer cells. Immune-Onc and The University of Texas published pioneering research in Nature illuminating the role of LILRB4 in immune suppression and tumor infiltration in acute myeloid leukemia (AML) and presented the rationale for targeting LILRB4 in solid tumors at the 2021 American Association for ...
Combining Zephyr’s proprietary artificial intelligence (AI) and algorithmic technology with NexImmune’s Artificial Immune Modulation (AIM) nanoparticle technology, the collaboration will seek to identify and validate optimal antigens and antigen cocktails for the development of potential new therapeutics in solid and hematological cancers. Under the ...
Axumin (fluciclovine F18) presentations Category: Genitourinary Cancer Title: Detectability Rates and Impact on Management From High-Sensitivity Total- Body 18F-Fluciclovine PET/CT Scans in Patients With Prostate Cancer Biochemical Recurrence Presenter: Soheila Fayeghi Azghadi, MD, Department of Radiation Oncology, Comprehensive Cancer ...
Ventura County Hematology Oncology Specialists is a comprehensive cancer center serving patients across Ventura and the surrounding coastal communities. ...
Daugherty is expanding his role with a very significant commitment to serve as medical monitor of our upcoming and future clinical trials as we seek to expand GP2’s potential to all HER2 positive breast cancer patients and to explore HER2 low breast cancer and other HER2 expressing cancers. ...
The collaboration will leverage Deep Lens’ artificial intelligence-based clinical trial matching solution, VIPERTM, and other support services to identify the right patients for oncology clinical trials for which they may be eligible, right at the time of their diagnosis. Ocala Oncology/Florida Cancer Affiliates specializes in hematology and oncology care ...
LAVA-051, LAVA’s lead product candidate, is a humanized bsTCE engineered to selectively target CD1d-expressing hematological cancers through activation of both gamma-delta T cells and type 1 natural killer T (NKT) cells. ...
B-cell lymphocytes are white blood cells circulating in the bloodstream: They play a critical role in our fight against infections and cancer. However, B-cell lymphocytes can become cancerous and transform into cancer cells, called lymphomas, which can ultimately lead to death. ...
ByAbologix
4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Dr. ...
About JW Therapeutics Co-founded by Juno Therapeutics and Wuxi AppTec, JW Therapeutics is a leading clinical and pre-clinical stage cell therapy company in China with an integrated platform focusing on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. JW Therapeutics' vision is to ...
Utrecht, The Netherlands & Philadelphia – LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 million (€71 million) Series C financing to fund the advancement of its pipeline and platform. ...